JPMorgan subsidiary discloses Kangji Medical privatization dealings

J.P. Morgan Securities PLC, identified as a Class (5) associate connected with the offeror for Kangji Medical Holdings Limited, has disclosed several dealings in Kangji Medical shares. These transactions, made for its own account and ultimately owned by JPMorgan Chase & Co., were reported on September 24, 2025, under Rule 22 of the Hong Kong Code on Takeovers and Mergers.

The disclosures detail three derivative transactions. On September 23, 2025, J.P. Morgan Securities PLC issued a derivative for 96,500 reference securities at a price of $8.8747, resulting in a total payment of $856,408.55. This derivative has a maturity date of February 10, 2026. On the same day, the firm closed out a derivative contract for 500,000 reference securities at $8.8685, receiving $4,434,226.

Additionally, on September 23, 2025, J.P. Morgan Securities PLC issued another derivative for 1,000 reference securities at $8.8765, amounting to $8,876.50, with a maturity date of September 24, 2027. Following these transactions, the resultant balance held by J.P. Morgan Securities PLC stands at 10,797,143 shares.